Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3
4(100.0%)
4Total
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02118961Phase 3Completed

Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents

Role: collaborator

NCT03188692Phase 3Completed

Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants

Role: collaborator

NCT02992925Phase 3Completed

Phase 3 Study of BK1310 in Healthy Infants

Role: collaborator

NCT03891758Phase 3Completed

Confirmatory Study of BK1310 in Healthy Infants

Role: collaborator

All 4 trials loaded